Profile data is unavailable for this security.
About the company
North China Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production and sales of pharmaceutical products. The Company's main products include anti-infective drugs, nephrology and immunomodulatory drugs, biotechnology drugs, cardiovascular and cerebrovascular and immunomodulatory agents, vitamins and health consumer products, nervous and blood system drugs, pharmaceutical intermediates, anti-epidemic drugs, pesticides and Veterinary drugs. The Company is also engaged in pharmaceutical and other logistics trade pharmaceuticals. The Company's products are mainly used in chemical pharmaceuticals, modern biotechnology drugs, vitamins and health consumer products, bioagricultural and veterinary drugs and other fields. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)9.71bn
- Net income in CNY79.38m
- Incorporated1992
- Employees10.16k
- LocationNorth China Pharmaceutical Co LtdNo. 388, Heping East RoadSHIJIAZHUANG 050015ChinaCHN
- Phone+86 31 185992839
- Fax+86 31 186060942
- Websitehttp://www.ncpc.com
More ▼
Mergers & acquisitions
| Acquired company | 600812:SHH since announced | Transaction value |
|---|---|---|
| North China Pharmaceutical Hebei Huamin Pharmaceutical Co Ltd | 16.21% | 93.38m |
Data delayed at least 15 minutes, as of Nov 26 2024 07:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shenzhen Chipscreen Biosciences Co Ltd | 656.24m | -70.33m | 8.60bn | 1.06k | -- | 5.24 | -- | 13.11 | -0.1709 | -0.1709 | 1.60 | 4.03 | 0.2022 | 2.34 | 4.47 | 620,847.90 | -2.17 | 1.32 | -2.44 | 1.54 | 86.24 | 93.29 | -10.72 | 6.97 | 2.76 | -0.5584 | 0.441 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 2.86bn | -24.94m | 8.76bn | 2.89k | -- | 1.35 | -- | 3.07 | -0.0074 | -0.0074 | 0.8379 | 1.89 | 0.2476 | 2.17 | 4.52 | 990,180.10 | -0.3138 | 2.26 | -0.4836 | 3.38 | 42.33 | 72.05 | -1.27 | 7.27 | 2.39 | -- | 0.1767 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| Shanghai Yizhong Pharmaceutical Co Ltd | 250.66m | 65.60m | 8.90bn | 43.00 | 136.74 | 6.16 | -- | 35.50 | 0.3163 | 0.3163 | 1.21 | 7.02 | 0.1669 | 0.5372 | 2.00 | 5,829,320.00 | 4.37 | -0.9181 | 4.57 | -0.9485 | 94.00 | 93.19 | 26.17 | -6.11 | 17.37 | -- | 0.0075 | -- | 52.68 | -- | 13.09 | -- | 20.44 | -- |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 1.24bn | 136.56m | 9.23bn | 1.81k | 67.57 | 5.89 | -- | 7.44 | 0.279 | 0.279 | 2.53 | 3.20 | 0.5011 | 0.5647 | 2.60 | 684,557.40 | 6.04 | -2.10 | 8.71 | -3.16 | 72.21 | 69.74 | 12.05 | -6.00 | 0.9873 | 21.00 | 0.0267 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
| Youcare Pharmaceutical Group Co Ltd | 4.23bn | 242.25m | 9.27bn | 3.18k | 38.28 | 2.53 | -- | 2.19 | 0.5382 | 0.5382 | 9.39 | 8.14 | 0.7221 | 2.33 | 5.37 | 1,330,727.00 | 4.11 | 7.11 | 6.04 | 11.65 | 58.62 | 64.14 | 5.70 | 8.07 | 1.52 | 105.13 | 0.1939 | 60.95 | -7.61 | 1.05 | -44.84 | -7.16 | 23.40 | -- |
| Harbin Pharmaceutical Group Co., Ltd. | 16.22bn | 613.05m | 9.29bn | 9.85k | 15.26 | 1.78 | -- | 0.573 | 0.2418 | 0.2418 | 6.38 | 2.07 | 1.15 | 6.29 | 3.47 | 1,646,115.00 | 4.78 | 0.7414 | 12.56 | 1.89 | 27.60 | 23.87 | 4.15 | 0.7294 | 1.11 | 36.80 | 0.3633 | 0.00 | 11.93 | 7.41 | -14.88 | 2.69 | -5.38 | -- |
| North China Pharmaceutical Co Ltd | 9.71bn | 79.38m | 9.35bn | 10.16k | 117.13 | 1.74 | -- | 0.9634 | 0.0465 | 0.0465 | 5.68 | 3.13 | 0.4492 | 2.67 | 4.34 | 955,385.00 | 0.6731 | -0.2978 | 1.54 | -0.7042 | 29.79 | 35.73 | 1.50 | -0.5985 | 0.5609 | 1.64 | 0.6482 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| Nanjing Vazyme Biotech Co Ltd | 1.40bn | 23.59m | 9.74bn | 2.70k | 395.90 | 2.44 | -- | 6.95 | 0.0615 | 0.0615 | 3.84 | 9.97 | 0.2644 | 1.06 | 3.57 | 519,483.10 | 0.4122 | 13.16 | 0.5237 | 15.92 | 70.21 | 70.50 | 1.56 | 23.92 | 4.17 | -- | 0.1436 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Chongqing Genrix Biophrmctcl Co Ltd | 13.56m | -779.42m | 9.98bn | 547.00 | -- | 4.24 | -- | 736.05 | -2.13 | -2.13 | 0.037 | 6.42 | 0.0039 | 0.1009 | 1.37 | 24,790.27 | -22.22 | -- | -23.06 | -- | 55.87 | -- | -5,747.82 | -- | 18.62 | -- | 0.2454 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.55bn | -34.96m | 10.13bn | 8.06k | -- | 1.23 | -- | 1.06 | -0.0412 | -0.0412 | 8.20 | 6.83 | 0.555 | 3.23 | 4.28 | 1,184,162.00 | -0.3467 | 1.95 | -0.5663 | 3.77 | 39.08 | 40.58 | -0.6248 | 3.43 | 0.6491 | -- | 0.3696 | 26.07 | -13.82 | 0.3618 | -119.05 | -- | -31.58 | -- |
Data as of Nov 26 2024. Currency figures normalised to North China Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
9.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Investment Corp. (Investment Management)as of 30 Sep 2023 | 54.92m | 3.37% |
| China Southern Asset Management Co., Ltd.as of 30 Sep 2023 | 16.53m | 1.01% |
| Da Cheng Fund Management Co., Ltd.as of 30 Sep 2023 | 16.45m | 1.01% |
| Yinhua Fund Management Co., Ltd.as of 30 Sep 2023 | 16.08m | 0.99% |
| GF Fund Management Co., Ltd.as of 30 Sep 2023 | 15.79m | 0.97% |
| Bosera Asset Management Co., Ltd.as of 30 Sep 2023 | 13.77m | 0.84% |
| Harvest Fund Management Co., Ltd.as of 30 Sep 2023 | 13.67m | 0.84% |
| The Vanguard Group, Inc.as of 31 Oct 2024 | 3.92m | 0.24% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 3.43m | 0.21% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 2.23m | 0.14% |
More ▼
Data from 30 Jun 2024 - 21 Nov 2024Source: FactSet Research Systems Inc.
